Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4

Human Heredity

Volumn 54, Issue 1, 2002, Pages 13-21

  Zeigler Johnson, Charnita M ^a,d   Walker, A H ^a   Mancke, B ^a   Spangler, E ^a   Jalloh, M ^c   McBride, S ^a   Deitz, A ^a   Malkowicz, S B ^a   Ofori Adjei, D ^b   Gueye, S M ^c   Rebbeck, T R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF GHANA   (Ghana)

^c Hopital General de Grand Yoff   (Senegal)

^d 908 Blockley Hall ^*  (United States)

Author keywords

CYP3A4; Ethnicity; Genotypes; Prostate cancer; SRD5A2

Indexed keywords

CYTOCHROME P450 3A4; STEROID 5ALPHA REDUCTASE; CHOLESTENONE 5ALPHA REDUCTASE; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; OXIDOREDUCTASE;

ADULT; AGED; ALLELE; ARAB; ARTICLE; ASIA; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; GHANA; GROUPS BY AGE; HUMAN; MALE; NEGRO; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENEGAL; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROSTATE TUMOR; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; CHOLESTENONE 5 ALPHA-REDUCTASE; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GHANA; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; SENEGAL; UNITED STATES;

EID: 18744393366     PISSN: 00015652     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066695     Document Type: Article

References (26)

1. Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, Gilliland F, Hankey B, Kolonel LN, Kosary C, Ross R, Severson R, West D: Prostate Cancer Trends 1973-1995. SEER Program, National Cancer Institute, NIH Pub. No. 99-4543, 1999.
2. Hsing AW, Tsao L, Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85(1):60-67.
3. Montie JE, Pienta KJ: Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology 1994;43(6):892-899.
4. Anwar R, Gilbey SG, New JP, Markham AF: Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5α-reductase type 2 gene (SRD5A2). J Clin Pathol: Mol Pathol 1997;50:51-52.
5. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi C-Y, Yu MC, Henderson BE, Reichardt JKV: A prevalent missense substitution that modulates activity of prostatic steroid 5α reductase. Cancer Res 1997;57:1020-1022.
6. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JKV: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. The Lancet 1999;354:975-978.
7. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90(16):1225-1229.
8. Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang C-S, Chern H-D, Olopade OI, Weber BL, Rebbeck TR: Characterization of an allelic variant in the niphedipine-specific element of CYP3A4:Ethnic distribution and implications for prostate cancer risk. Hum Mutat: Mutation in Brief 1998, p 191.
9. Tayeb MT, Clark C, Ameyaw M-M, Haites NE, Evans DAP, Tariq M, Mobarek A, Ofori-Adjei D, McLeod HL: CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 2000;10:753-756.
10. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS: Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8(10):901-905.
11. Rebbeck TR, Walker AH, Jaffe JM, White DL, Wein AJ, Malkowicz SB: Glutathione S-transferase-mu (GSTM1) and -theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8(4 Pt. 1):283-287.
12. Kelada SN, Kardia SL, Walker AH, Wein AJ, Malkowicz SB, Rebbeck TR: The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: Genotype-environment interaction with smoking. Cancer Epidemiol Biomarkers Prev 2000;9(12):1329-1334.
13. Walker AH, Najarian D, White DL, Jaffe JM, Kanetsky PA, Rebbeck TR: Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environ Health Perspect 1999;107(7):517-520.
14. Vilchis F, Hernandez D, Canto P, Mendez JP, Chavez B: Codon 89 polymorphism of the human 5α-steroid reductase type 2 gene. Clin Genet 1997;51:399-402.
15. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T: Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993;218:585-595.
16. Lunn RM, Bell DA, Mohler JL, Taylor JA: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20(9):1727-1731.
17. Febbo PG, Kantoff PW, Platz EA, Casey D, Batter S, Giovannucci E, Hennekens CH, Stampfer MJ: The V89L Polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res 1999;59:5878-5881.
18. Margiotti K, Sangiuolo F, De Luca A, Froio F, Pearce CL, Ricci-Barbini V, Micali F, Bonafe M, Franceschi C, Dallapiccola B, Novelli G, Reichardt JKV: Evidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patients. Disease Markers 2000;16:147-150.
19. Hsing AW, Chen C, Chokkalingam AP, Gao Y-T, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JKV: Polymorphic markers in the SRD5A2 gene and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2001;10:1077-1082.
20. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJJ, Wilkinson GR: CYP3A4 activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82-91.
21. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ: Prospective study of sex hormone levels and risk of prostate cancer. JNCI 1997;88(16):1118-1126.
22. Pienta KJ, Goodson JA, Esper PS: Epidemiology of prostate cancer: Molecular and environmental clues. Urology 1996;48(5):676-683.
23. Meikle AW, Smith JA Jr: Epidemiology of prostate cancer. Urol Clin N Am 1990;17(4):709-718.
24. Osegbe DN: Prostate cancer in Nigerians: Facts and nonfacts. J Urol 1997;157:1340-1343.
25. Ferlay J, Bray F, Pisani P, Perkin DM: Globocan 2000: Cancer Incidence, Mortality, and Prevalence Worldwide, Version 1.0. IARC CancerBase #5 Lyon, IARCPress, 2001.
26. Dawam D, Rafindadi AH, Kalayi GD: Benign prostatic hyperplasia and prostate carcinoma in native Africans. BJU International 2000;85:1074-1077.